Lipoprotein abnormalities in patients with type 2 diabetes and metabolic syndrome.
Cardiovascular disease remains the leading cause of death in men and women in the United States. Aggressive treatment of insulin resistance and its associated lipid abnormalities remains a top priority for preventing cardiovascular morbidity and mortality.